Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment

References

• Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39(4):265–292. doi:10.1016/S0039-6257(05)80105-5.
   PubMed Web of Science ®Google Scholar
• Herbort CP, Abu El Asrar AM, Takeuchi M, et al. Catching the therapeutic window of opportunity in early initial-onset Vogt–Koyanagi–Harada uveitis can cure the disease. Int Ophthalmol. 2019;39(6):1419–1425.doi:10.1007/s10792-018-0949-4.
   PubMed Web of Science ®Google Scholar
• Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14(2):87–90. doi:10.1080/09273940500536766.
   PubMed Web of Science ®Google Scholar
• Herbort Jr CP, Abu El Asrar AM, Yamamoto JH, et al. Reappraisal of the management of Vogt–Koyanagi–Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol. 2017;37(6):1383–1395.doi:10.1007/s10792-016-0395-0.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2017;95(1):85–90. doi:10.1111/aos.13189.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Taylor SRJ, Lightman S. Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation? Ophthalmologica. 2013;230(3):109–115. doi:10.1159/000351426.
   PubMed Web of Science ®Google Scholar
• Becker MD, Adamus G, Davey MP, Rosenbaum JT. The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm. 2000;8(2):93–100. doi:10.1076/0927-3948(200006)8:2;1-0;ft093.
   PubMed Web of Science ®Google Scholar
• Inomata H, Sakamoto T. Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus. Curr Eye Res. 1990;9(sup1):35–40. doi:10.3109/02713689008999417.
   PubMed Web of Science ®Google Scholar
• Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2011;1(4):177–180. doi:10.1007/s12348-011-0027-9.
   PubMedGoogle Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246–252.doi:10.1111/j.1756-185X.2010.01546.x.
   PubMed Web of Science ®Google Scholar
• Kaegi C, Wuest B, Schreiner J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10(September):1–18.doi:10.3389/fimmu.2019.01990.
   PubMedGoogle Scholar
• Caso F, Rigante D, Vitale A, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. 2015;34(10):1817–1820.doi:10.1007/s10067-014-2781-1.
   PubMed Web of Science ®Google Scholar
• Umran RMR, Shukur ZYH. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease. Mod Rheumatol. 2018;28(1):197–199. doi:10.3109/14397595.2015.1071234.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dheyab A, Khatib D, Struyf S, Van Damme J, Opdenakker G. Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2020;1–8. doi:10.1080/09273948.2020.1820531.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652.doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Fabro F, Herbort CP. Need for quantitative measurement methods for posterior uveitis: comparison of dual FA/ICGA angiography, EDI-OCT choroidal thickness and SUN vitreous haze evaluation in stromal choroiditis. Klin Monbl Augenheilkd. 2018;235(4):424–435. doi:10.1055/s-0043-124966.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.doi:10.1016/S0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Iwahashi C, Okuno K, Hashida N, Nakai K, Ohguro N, Nishida K. Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals. Jpn J Ophthalmol. 2015;59(3):157–163. doi:10.1007/s10384-015-0377-1.
   PubMed Web of Science ®Google Scholar
• Bouchenaki N, Morisod L, Herbort CP. Vogt-Koyanagi-Harada syndrome: importance of rapid diagnosis and rapid therapeutic intervention. Klin Monbl Augenheilkd. 2000;216(5(216)):290–294. doi:10.1055/s-2000-10987.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2010;30(1):41–50. doi:10.1007/s10792-008-9288-1.
   PubMedGoogle Scholar
• Cunningham ET, Rathinam SR, Tugal-Tutkun I, Muccioli C, Zierhut M. Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2014;22(4):249–252. doi:10.3109/09273948.2014.939530.
   PubMed Web of Science ®Google Scholar
• Howe L, Stanford M, Graham E, Marshall J. Indocyanine green angiography in inflammatory eye disease. Eye. 1998;12(5):761–767. doi:10.1038/eye.1998.199.
   PubMedGoogle Scholar
• Bouchenaki N, Cimino L, Auer C, Tran VT, Herbort CP. Assessment and classification of choroidal vasculitis in posterior uveitis using indocyanine green angiography. Klin Monbl Augenheilkd. 2002;219(4):243–249. doi:10.1055/s-2002-30661.
   PubMed Web of Science ®Google Scholar
• Herbort CP, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up. Int Ophthalmol. 2007;27(2–3):173–182. doi:10.1007/s10792-007-9060-y.
   PubMedGoogle Scholar
• Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina. 2011;31(3):510–517.doi:10.1097/IAE.0b013e3181eef053.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Keino H, Okada AA, et al. Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease. Retina. 2012;32(10):2061–2069.doi:10.1097/IAE.0b013e318256205a.
   PubMed Web of Science ®Google Scholar
• Jap A, Chee SP. The role of enhanced depth imaging optical coherence tomography in chronic Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2017;101(2):186–189. doi:10.1136/bjophthalmol-2015-308091.
   PubMed Web of Science ®Google Scholar
• Chee SP, Chan SWN, Jap A. Comparison of enhanced depth imaging and swept source optical coherence tomography in assessment of choroidal thickness in Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2017;25(4):528–532. doi:10.3109/09273948.2016.1151896.
   PubMed Web of Science ®Google Scholar
• Nakai K, Gomi F, Ikuno Y, et al. Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography. Graefe’s Arch Clin Exp Ophthalmol. 2012;250(7):1089–1095.doi:10.1007/s00417-011-1910-7.
   PubMed Web of Science ®Google Scholar
• Ishibazawa A, Kinouchi R, Minami Y, Katada A, Yoshida A. Recurrent Vogt-Koyanagi-Harada disease with sensorineural hearing loss and choroidal thickening. Int Ophthalmol. 2014;34(3):679–684. doi:10.1007/s10792-013-9849-9.
   PubMed Web of Science ®Google Scholar
• Ikeda N, Ikeda T, Iwami H. Detection of asymptomatic choroiditis by fundus examination in Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2017;25(6):830–833. doi:10.1080/09273948.2016.1184283.
   PubMed Web of Science ®Google Scholar
• Zmuda M, Tiev KP, Knoeri J, Successful HE. Use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2013;21(4):310–316. doi:10.3109/09273948.2013.775312.
   PubMed Web of Science ®Google Scholar